Cargando…
Cenerimod, a novel selective S1P(1) receptor modulator with unique signaling properties
Sphingosine‐1‐phosphate receptor 1 (S1P(1)) modulators sequester circulating lymphocytes within lymph nodes, thereby preventing potentially pathogenic autoimmune cells from exiting into the blood stream and reaching inflamed tissues. S1P(1) receptor modulation may thus offer potential to treat vario...
Autores principales: | Piali, Luca, Birker‐Robaczewska, Magdalena, Lescop, Cyrille, Froidevaux, Sylvie, Schmitz, Nicole, Morrison, Keith, Kohl, Christopher, Rey, Markus, Studer, Rolf, Vezzali, Enrico, Hess, Patrick, Clozel, Martine, Steiner, Beat, Bolli, Martin H., Nayler, Oliver |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5723703/ https://www.ncbi.nlm.nih.gov/pubmed/29226621 http://dx.doi.org/10.1002/prp2.370 |
Ejemplares similares
-
Desensitization by Progressive Up-Titration Prevents First-Dose Effects on the Heart: Guinea Pig Study with Ponesimod, a Selective S1P(1) Receptor Modulator
por: Rey, Markus, et al.
Publicado: (2013) -
Cenerimod, a selective S1P(1) receptor modulator, improves organ-specific disease outcomes in animal models of Sjögren’s syndrome
por: Gerossier, Estelle, et al.
Publicado: (2021) -
Preclinical to clinical translation of cenerimod, a novel S1P(1) receptor modulator, in systemic lupus erythematosus
por: Strasser, Daniel S, et al.
Publicado: (2020) -
GPCR-induced YAP activation sensitizes fibroblasts to profibrotic activity of TGFβ1
por: Zmajkovicova, Katarina, et al.
Publicado: (2020) -
Therapeutic Use of a Selective S1P(1) Receptor Modulator Ponesimod in Autoimmune Diabetes
por: You, Sylvaine, et al.
Publicado: (2013)